

Community-acquired pathogens associated with prolonged coughing in children: a prospective cohort study

F. G. A. Versteegh¹, G. J. Weverling², M. F. Peeters³, B. Wilbrink⁴, M. T. M. Veenstra-van Schie¹, J. M. van Leeuwen-Gerritsen¹, E. A. N. M. Mooi-Kokenberg⁵, J. F. P. Schellekens⁴ and J. J. Roord⁶

¹Groene Hart Ziekenhuis, Department of Pediatrics, Gouda, ²Academic Medical Center, Department of Clinical Epidemiology and Biostatistics, University of Amsterdam, Amsterdam, ³St Elisabeth Hospital, Department of Medical Microbiology, Tilburg, ⁴National Institute of Public Health and the Environment, Diagnostic Laboratory of Infectious Diseases and Perinatal Screening, Bilthoven, ⁵Groene Hart Ziekenhuis, Department of Medical Microbiology and Infection Control, Gouda and ⁶Free University Medical Center, Department of Pediatrics, Amsterdam, The Netherlands

ABSTRACT

A 2-year prospective study was performed of children with prolonged coughing to investigate the frequency of different respiratory pathogens, the rate of mixed infections, and possible differences in severity of disease between single and mixed infections. Sera from 135 children (136 episodes of prolonged coughing lasting 1–6 weeks) were tested for antibodies to different viruses and bacteria. Swabs were taken for culture and PCR to detect different viral and bacterial pathogens. One or more pathogens were found in 91 (67%) patients. One infectious agent was found in 49 (36%) patients, two agents in 35 (26%) patients, and more than two agents in seven (5%) patients. The most frequent pathogens encountered were rhinovirus ($n = 43$; 32%), *Bordetella pertussis* ($n = 23$; 17%) and respiratory syncytial virus ($n = 15$; 11%). The most frequent mixed infection was *B. pertussis* and rhinovirus ($n = 14$; 10%). No significant differences in clinical symptoms were observed between patients with or without pathogens; however, patients with mixed infections were significantly older. There was a strong seasonal influence on the number of infections, but not on the number of mixed infections. In children with prolonged coughing, there was a high frequency of mixed infections regardless of the season. However, mixed infection was not associated with increased disease severity. No clinical symptoms were found that allowed discrimination between specific pathogens.

Keywords *Bordetella pertussis*, children, community-acquired respiratory tract infections, prolonged coughing, respiratory tract infection, respiratory viruses

Original Submission: 21 November 2004; **Revised Submission:** 3 April 2005; **Accepted:** 24 April 2005

Clin Microbiol Infect 2005; 11: 801–807

INTRODUCTION

Prolonged coughing is a frequent symptom in children and is often associated with respiratory tract infection [1]. Although prolonged coughing is a prominent feature of infection with *Bordetella pertussis*, infections with other respiratory tract pathogens may also cause prolonged coughing [2]. Mixed infections with a combination of two or more pathogens occur, but data on clinical

manifestations of combined infections derived from retrospective studies are often difficult to interpret [2–5]; nevertheless, it has been suggested that mixed infections may result in more severe illness, especially in younger children [3,4,6]. In an earlier retrospective observational study (unpublished data) involving 81 children with serologically proven *B. pertussis* infection, evidence was found in 28% of the children for concomitant infections with other respiratory tract pathogens. It is known that many such pathogens may cause prolonged coughing in children, but prolonged coughing is not always caused by a respiratory tract infection [1,7,8]. The present study investigated the role of different

Corresponding author and reprint requests: F. G. A. Versteegh, Groene Hart Ziekenhuis, Department of Pediatrics, Postbox 1098, 2800 BB Gouda, The Netherlands
E-mail: versteegh@linuxmail.org

respiratory pathogens in prolonged coughing in children, as well as the frequency of occurrence of possible mixed infections. In addition, the severity of disease in patients with one or more pathogens was compared with that in patients for whom no pathogens were detected.

MATERIALS AND METHODS

Patients

Participating patients (aged ≤ 18 years) were those referred with persistent coughing to the outpatient clinic of the Department of Pediatrics at Groene Hart hospital, a 500-bed general hospital in Gouda, The Netherlands, between September 2001 and September 2003. Disease duration was defined as the time between onset of symptoms and first visit to the hospital. The definition of prolonged, chronic or persistent cough has varied from 5 days to > 1 month [2,7,9–12]. Patient selection in the present study was based on a persistent cough lasting 1–6 weeks. Patients with aspiration of a foreign body or patients known to have cystic fibrosis were excluded. Blood samples were analysed at the first visit for erythrocyte sedimentation rate, C-reactive protein level, leukocyte count and differentiation, and serological evidence of respiratory pathogens (see below). Oropharyngeal, nasal and nasopharyngeal swabs were taken for culture and PCR analysis for respiratory pathogens (see below). When the disease duration on the first visit was < 14 days, serological tests were repeated after 2 weeks, except for *B. pertussis*. When serology and PCR results at the first visit were negative for *B. pertussis*, the serological testing was repeated 4 weeks later (after 6 weeks for children aged < 1 year). The patients, or their parents, were asked to complete a questionnaire regarding symptoms, previous diseases and vaccination status. All gave their written informed consent to participate in the study. A follow-up telephone interview was conducted c. 4 weeks after enrolment. The study was approved by the Medical Ethics Committee of the hospital. A healthy control group was not included in this study.

Serology

Positive serology for *B. pertussis* was defined as at least a four-fold increase in IgG to pertussis toxin (IgG-PT) in paired sera to a level of ≥ 20 U/mL, or a high IgG-PT concentration in a single serum, i.e., > 100 U/mL, as measured by the in-house IgG-PT ELISA of the National Institute of Public Health and the Environment (RIVM), Bilthoven, The Netherlands [13]. The interpretation criteria of the IgG-PT ELISA have been shown to have a sensitivity and specificity of 90% and 97%, respectively [14].

All sera were tested for antibodies to respiratory syncytial virus (RSV), influenza viruses A and B, adenovirus, parainfluenza viruses 1, 2 and 3, *Mycoplasma pneumoniae*, *Chlamydia* spp. and *Coxiella burnetii* by the Regionaal Medisch Microbiologisch Laboratorium (Rotterdam, The Netherlands) with the complement fixation method (Serion Immunodiagnostica, Würzburg, Germany). Two-point serology against these pathogens was considered proof of a recent infection when there was a four-fold or more increase or decrease in titre. In

one-point serology, a titre ≥ 128 was considered to indicate recent infection, while a titre ≥ 64 was considered to be equivocal, except for *C. burnetii* (≥ 4 equivocal) and *Chlamydia* (≥ 8 equivocal) [15]. An indirect IgM immunofluorescence assay (Serion Immunodiagnostica) was performed when the complement fixation method was equivocal. A positive IgM result, together with an equivocal complement fixation test result, was also considered to be proof of a recent infection. As there are serological cross-reactions between parainfluenza virus types 1, 2 and 3, these results were reported together.

PCR

Detection of *B. pertussis* and *Bordetella parapertussis* was by PCR, using a MagNa Pure LC Total Nucleic Acid Isolation Kit (Roche Diagnostics, Indianapolis, IN, USA) and primer pairs based on IS481 and IS1001. The final PCR product was analysed by gel electrophoresis and by dot-blot hybridisation [16,17].

PCRs for *Chlamydia pneumoniae*, *M. pneumoniae*, influenza viruses A and B, coronaviruses 229E and OC43, RSV, human metapneumovirus, rhinovirus and enterovirus were performed on a nasal and a throat swab. A negative control (virus transport medium) was included for every four clinical samples. A positive control containing each pathogen was included in each DNA and RNA extraction and PCR run. DNA was isolated with a proteinase K and sodium dodecyl sulphate extraction, essentially as described previously [18]. RNA was isolated with a High Pure RNA isolation kit (Roche), with the addition of poly(A) RNA as carrier, according to the manufacturer's instructions. An aliquot of the isolated DNA was used in a PCR detecting either *M. pneumoniae* [18] or *Chlamydia pneumoniae* [19]. An aliquot of the eluted RNA preparation was used for the detection of rhino/enterovirus [20], influenza viruses A [21] and B [22], and human metapneumovirus [23] in separate single-tube RT-PCRs. RSV [24] and coronaviruses OC43 and 229E [25] were amplified in a multiplex single-tube nested RT-PCR.

Culture for respiratory bacterial pathogens

An oropharyngeal swab was inoculated on to a blood agar plate, a blood agar plate containing oxolinic acid (10 mg/L), and a chocolate agar plate. β -Haemolytic group A streptococci, *Haemophilus influenzae*, *Streptococcus pneumoniae* and *Moraxella catarrhalis* were considered to be potential pathogens. *Staphylococcus aureus*, *Neisseria meningitidis*, non-group A β -haemolytic streptococci and *Candida albicans* were also reported, but were not considered to be pathogens. Only cultures showing significant growth were considered to be positive [26]. Non-pathogenic oropharyngeal flora (e.g., viridans streptococci, diphtheroids, coagulase-negative staphylococci) were not reported.

Statistical analysis

For the description of patient characteristics, median and interquartile ranges were calculated. A statistical comparison was made between three groups of children, i.e., children in whom no pathogen was detected, children with only one pathogen, and children with two or more pathogens. The chi-square test or, for continuous variables, analysis of variance (ANOVA) was used.

RESULTS

During the 2-year period, 152 patients were referred for prolonged coughing, of whom 11 refused to participate in the study. Five patients were not included because of protocol violation. The remaining 136 episodes related to 135 patients, since one patient had two episodes of coughing with an interval of 5.2 months, which were considered as two independent events. Patient characteristics are summarised in Table 1. One or more pathogens were found in 91 (67%) patients. Of these patients, 49 (36%) had one pathogen, 35 (26%) had two pathogens, six (4%) patients had three pathogens, and one (1%) had four pathogens. The presence of more than one pathogen in patients was detected throughout the entire year of the study in children of all ages. The different pathogens detected are listed in Table 2.

All respiratory pathogens found in the present study were considered to be possible causes of prolonged coughing, even though patients may also be colonised by some of the pathogens found. The pathogens detected most frequently were rhinovirus (43 patients; 47%), *B. pertussis* (23 patients; 25%) and RSV (15 patients; 16%) (Table 2). In the 42 patients with a mixed infection (Table 3), the most frequent combination was *B. pertussis* and rhinovirus ($n = 14$).

Fifteen of the 27 positive bacterial cultures were found in patients with more than one pathogen (Table 3). There were 11 patients with a positive oropharyngeal culture and one other pathogen. In only one of these patients (with a C-reactive protein level of 109 mg/L) was the bacterial infection considered to influence the course of the disease, while the other ten patients showed no clinical sign of a bacterial infection. It was difficult to assess whether the results for these ten patients represented a mixed or a consecutive

infection, or whether the bacteria found simply reflected carriage. Therefore, these cases were not considered to be possible mixed infections. On the basis of serology, PCR and culture, 21 (24%) of the remaining 32 patients with more than one pathogen detected were considered to have a possible mixed infection (14 of these had a positive PCR for two or three pathogens), nine had a consecutive infection, and two had both.

There were no significant differences between patients with or without pathogens with respect to disease duration before presentation, disease severity (antibiotics, hospitalisation, length of stay, coughing and other symptoms, such as headache, sore throat or pain) or vaccination status (Tables 1 and 4). However, children with more than one pathogen were, on average, 3 years older than children with one or no pathogens (Table 1; $p < 0.005$). Although there were no significant differences in coughing during different parts of the day, there seemed to be a tendency for children with more than one pathogen to cough more frequently (Table 4). There were no significant differences in coughing or other symptoms for the three pathogens found most frequently, except that patients with *B. pertussis* had less fever. All patients recovered, although the time to recovery was not recorded accurately. Data regarding coughing in the family or other potential contaminators were not recorded.

DISCUSSION

To our knowledge, this is the first study in which a broad spectrum of respiratory pathogens has been studied prospectively in children selected by persistent coughing. As found in the present study, rhinovirus is associated frequently with respiratory disease in children of all ages [27–30], with incidences ranging from 21% to 40% in

Table 1. Clinical data for all patients, grouped according to the number of potential pathogens isolated

| | All patients | No pathogen detected | One pathogen detected | More than one pathogen detected | p value |
|---|---------------|----------------------|-----------------------|---------------------------------|---------|
| <i>n</i> | 136 | 45 (33%) | 49 (36%) | 42 (31%) | |
| Age, years (median and interquartile range) | 2.7 (0.6–6.4) | 1.3 (0.6–5.8) | 1.0 (0.4–5.0) | 4.4 (1.8–9.0) | 0.005 |
| Male gender | 80 (59%) | 27 (60%) | 31 (63%) | 22 (52%) | 0.56 |
| Disease duration, days (median and interquartile range) ^a | 14 (10–20) | 15 (13–21) | 14 (9–17) | 14 (9–20) | 0.33 |
| Vaccination status ^b | 124 (92%) | 41 (91%) | 44 (90%) | 39 (95%) | 0.64 |
| Admission to hospital | 51 (38%) | 16 (36%) | 22 (45%) | 13 (31%) | 0.37 |
| Length of stay following admission, days (median and interquartile range) | 5 (3–7) | 3.5 (2–6) | 5 (3–7) | 5 (4–7) | 0.49 |
| Antibiotics prescribed | 68 (50%) | 22 (49%) | 23 (47%) | 23 (55%) | 0.75 |

^aDisease duration: time between first day of illness and first presentation in the hospital.

^bInformation on vaccination status (regular vaccinations appropriate for age) was missing for one patient.

| | Children with pathogen <i>n</i> = 91 (67%) ^a | Diagnostic test | | | |
|--|---|-----------------|-----|------|---------|
| | | Serology | PCR | Both | Culture |
| Pathogens | | | | | |
| <i>Bordetella pertussis</i> | 23 (25%) | 3 | 8 | 12 | ND |
| <i>Bordetella parapertussis</i> | 1 (1%) | ND | 1 | ND | ND |
| Influenza virus A or B | 5 (5%) | 5 | 0 | 0 | ND |
| Adenovirus | 6 (7%) | 6 | ND | ND | ND |
| <i>Mycoplasma pneumoniae</i> | 6 (7%) | 4 | 1 | 1 | ND |
| Parainfluenza virus | 9 (10%) | 9 | ND | ND | ND |
| Respiratory syncytial virus | 15 (16%) | 14 | 1 | 0 | ND |
| Rhinovirus | 43 (47%) | ND | 43 | ND | ND |
| Human metapneumovirus | 1 (1%) | ND | 1 | ND | ND |
| Enterovirus | 4 (4%) | ND | 4 | ND | ND |
| <i>Chlamydia pneumoniae</i> | 1 (1%) | 0 | 0 | 1 | ND |
| Carriage organisms | | | | | |
| <i>Streptococcus pneumoniae</i> | 1 (1%) | ND | ND | ND | 1 |
| <i>Haemophilus parainfluenzae</i> | 7 (8%) | ND | ND | ND | 7 |
| <i>Staphylococcus aureus</i> | 1 (1%) | ND | ND | ND | 1 |
| <i>Haemophilus influenzae</i> non-type b | 12 (13%) | ND | ND | ND | 12 |
| <i>Haemophilus influenzae</i> type b | 1 (1%) | ND | ND | ND | 1 |
| β-Haemolytic streptococci group C | 1 (1%) | ND | ND | ND | 1 |
| β-Haemolytic streptococci group G | 1 (1%) | ND | ND | ND | 1 |
| β-Haemolytic streptococci group B | 1 (1%) | ND | ND | ND | 1 |
| <i>Candida albicans</i> | 2 (2%) | ND | ND | ND | 2 |
| Total | 141 | | | | |

^aTwo or more pathogens were found in 42 patients.

Table 2. Respiratory pathogens detected in the study and means of detection

Table 3. Combinations of respiratory pathogens detected in 42 patients with more than one pathogen

| | <i>Bordetella pertussis</i> | <i>Bordetella parapertussis</i> | Influenza virus A or B | Adenovirus | <i>Mycoplasma pneumoniae</i> | Parainfluenza virus | Respiratory syncytial virus | Rhinovirus |
|--|-----------------------------|---------------------------------|------------------------|------------|------------------------------|---------------------|-----------------------------|----------------|
| Pathogens | | | | | | | | |
| <i>Bordetella pertussis</i> | | | | | | | | |
| <i>Bordetella parapertussis</i> | | | | | | | | |
| Influenza virus A or B | | | | | | | | |
| Adenovirus | 2 ^a | 1 ^b | 1 | | | | | |
| <i>Mycoplasma pneumoniae</i> | | | | | | | | |
| Parainfluenza virus | | | | | | | | |
| Respiratory syncytial virus | 1 | | 1 | | | 1 | | |
| Rhinovirus | 14 ^c | | | 2 | | 2 ^d | 2 ^a | |
| Human metapneumovirus | | | | | | | | |
| Enterovirus | 1 | | 1 | | | | 1 | |
| <i>Chlamydia pneumoniae</i> | | | | | | | | |
| Carriage organisms | | | | | | | | |
| <i>Streptococcus pneumoniae</i> | | | | | | 1 | | |
| <i>Haemophilus parainfluenzae</i> | | | | | 1 | | | 1 |
| <i>Staphylococcus aureus</i> | | | | | | | | |
| <i>Haemophilus influenzae</i> non-type b | | | | | | 1 | 3 | 1 |
| <i>Haemophilus influenzae</i> type b | | | | | 1 | | | |
| β-Haemolytic streptococci group C | | | | | 1 ^e | | | |
| β-Haemolytic streptococci group G | | | | | | | | |
| β-Haemolytic streptococci group B | | | | | | | | 1 ^c |
| <i>Candida albicans</i> | | | | | | | 1 | |

Three pathogens were detected in six patients, and four pathogens in one patient.

^aOne patient also had *Haemophilus parainfluenzae*.

^bAlso respiratory syncytial virus.

^cOne patient also had *Mycoplasma pneumoniae*.

^dOne patient also had respiratory syncytial virus and *Haemophilus parainfluenzae*.

^eOne patient also had *Haemophilus influenzae* non-type b.

children with overt infection, but with an incidence of 20% in one study of children without nasal symptoms [29]. Rhinovirus can cause mild upper airway disease, and can also play a role in more severe respiratory tract infection. It is difficult to compare the results regarding the frequency of various pathogens obtained in the present study with those of other studies on respiratory tract infections among children, since

such studies have been mainly retrospective [2,4–6,8–10,30–44]. The incidence of pathogenic agents responsible for respiratory infection in the present study was 67%, which is comparable with the results of some studies (incidences of 56–64%) [2,9,33,40], but different from those of others (incidences of 80–90%) [9,30,37].

A relatively high incidence (10% of all patients) of co-infection with rhinovirus and *B. pertussis*

Table 4. Number (%) of patients with coughing and other symptoms

| | No pathogen | One pathogen | More than one pathogen | <i>Bordetella pertussis</i> | Rhinovirus | Respiratory syncytial virus |
|------------------------------------|-------------|--------------|------------------------|-----------------------------|------------|-----------------------------|
| All (<i>n</i> = 135) ^a | 45 (33) | 49 (36) | 41 (31) ^a | 23 (17) | 43 (32) | 15 (11) |
| Coughing | | | | | | |
| Morning (<i>n</i> = 82) | 25 (30) | 26 (32) | 31 (38) | 16 (20) | 30 (37) | 11 (13) |
| Afternoon (<i>n</i> = 70) | 22 (31) | 21 (30) | 27 (39) | 17 (24) | 26 (37) | 9 (13) |
| Evening (<i>n</i> = 88) | 25 (28) | 32 (36) | 31 (35) | 20 (23) | 31 (35) | 9 (10) |
| Night (<i>n</i> = 89) | 25 (28) | 32 (36) | 32 (36) | 17 (19) | 29 (33) | 13 (15) |
| Symptoms | | | | | | |
| Fever (<i>n</i> = 47) | 18 (38) | 14 (30) | 15 (32) | 1 (2) | 13 (28) | 7 (15) |
| Tachypnoea (<i>n</i> = 51) | 16 (31) | 20 (39) | 15 (29) | 6 (12) | 15 (29) | 9 (18) |
| Dyspnoea (<i>n</i> = 63) | 22 (35) | 21 (33) | 20 (32) | 9 (14) | 14 (22) | 7 (11) |

There were no significant differences, except that there was less fever associated with *Bordetella pertussis* infection.

^aData missing for one patient.

was observed. Among children infected with *B. pertussis*, co-infection with rhinovirus was found in 61% of cases. The role of *B. pertussis* in rhinovirus infection is complicated; indeed it has been reported that rhinovirus-induced changes in airway smooth muscle responsiveness in isolated rabbit and human airway smooth muscle tissue, as well as cultured airway smooth muscle cells, were largely prevented by pretreating the tissues with pertussis toxin or with a monoclonal blocking antibody to intercellular adhesion molecule-1, the principal endogenous receptor for most rhinoviruses [45]. This might indicate that co-infection with rhinovirus and *B. pertussis* is not as severe as might be expected. This hypothesis was supported by the observation in the present study that coughing and other clinical symptoms did not differ significantly from those in patients infected with either rhinovirus or *B. pertussis*, and the fact that, although there was a co-infection incidence of 61% with *B. pertussis* and rhinovirus, there was less fever in the co-infected group, as would be expected with *B. pertussis* infection alone. In agreement with other studies [2,9,31,44,46], no pathogens or positive serological results were obtained for 33% of the patients in the present study, although pathogens as yet unidentified may be associated with prolonged coughing in this group, as exemplified by the recent description of human metapneumovirus and human coronavirus NL63 [23,47,48].

Asymptomatic children were not recruited as a control group, since this was considered to be too distressing for children. However, the occurrence of pathogens in subjects without coughing would provide data on the incidence of carriage of potential pathogens without disease. Some studies have observed fewer viruses in non-symptomatic

controls compared with patients [32–35]. Gunnarsson *et al.* [31] isolated *S. pneumoniae*, *H. influenzae* and *Moraxella catarrhalis* more frequently from patients with long-standing cough than from healthy individuals of the same age. In a case-control study involving general practitioner patients of all ages with acute respiratory tract infections, significantly fewer viruses were detected in controls than in patients (19% vs. 54%) [36].

Most patients with a positive culture for pathogenic bacteria will not have a bacterial respiratory tract infection. Since carriage rates for potential pathogenic bacteria in healthy young children may vary between 11% and 48% [31,49], it is difficult to establish whether these bacteria may have a clinical influence. In a logistic regression analysis, although not statistically significant, there was a greater association with coughing in the morning for pathogens diagnosed by PCR or serology than for pathogens diagnosed by oropharyngeal bacterial culture (OR, 2.0 vs. 0.8). Similar associations were found when coughing patterns at other times of the day were analysed. Therefore, it can be argued that a positive bacterial oropharyngeal culture is of little value in the search for respiratory pathogens causing prolonged cough.

More than one pathogen was detected in 31% of all children. The presence of one (viral) respiratory pathogen may predispose to a second or third (bacterial) infection [39,42,46]. The proportion of mixed infections reported in other studies shows large variations (10–74%) [9,33,34,38,39,46]. There is a significant seasonal influence on disease, so the observation period of the present study was 2 years. In the second year, a low incidence of prolonged coughing was observed, with few

referrals, perhaps associated with the mild winter of 2002–2003 and the warm summer of 2003 in The Netherlands. However, the frequency of isolation of two or more pathogens during both years of the study in every season remained the same. Previous studies have associated mixed infections with more severe disease [3–6,43,44,48], but this was not the case in the present study (Table 1). Generally, it seemed that there was one dominant pathogen, with no cumulative or synergic effect of a second pathogen. Patients with more than one pathogen were significantly older than those with one or no pathogens, which might indicate that they were more seriously ill than children of similar age with one or no detectable pathogen. This is supported by the fact that there was a slight tendency for coughing to be more frequent in patients with two or more pathogens (Table 4).

In summary, one pathogen was detected in 36% of children with prolonged coughing, and more than one pathogen in 31%. There was a strong seasonal influence on the number of cases, but not on the pathogens found or on the percentage of multiple infections. Clinical data did not distinguish between pathogens, or whether or not pathogens were found. There was no increase in disease severity, with respect to symptoms and hospitalisation, for cases of mixed or consecutive infection, although this group was significantly older, suggesting that they had a more severe disease than their peer groups with one or no pathogens. Obviously, not all possible pathogens found will cause illness, although it is still not clear whether or how the presence of a colonising potential respiratory pathogen influences or facilitates infection caused by other possible pathogens. It is therefore important to extend studies on respiratory tract infections associated with more than one pathogen in order to evaluate their influence on disease severity.

ACKNOWLEDGEMENTS

We thank J. C. M. Hoekx, E. G. H. van Leer, J. S. Starreveld, C. V. Tjon Pian Gi and all the interns of the Department of Pediatrics at Groene Hart Hospital for their participation in this study. We thank B. McClements for revising the text, and J. Buitenwerf and R. Woudenberg (Regionaal Medisch-Microbiologisch Laboratorium, Rotterdam, The Netherlands) for helping to interpret the serological data. We thank Abbott and the Groene Hart Hospital for their support, which made this study possible. This study was supported by an unrestricted grant from Abbott.

REFERENCES

- de Jongste JC, Shields MD. Cough. 2: Chronic cough in children. *Thorax* 2003; **581**: 998–1003.
- Wirsing von König CH, Rott H, Bogaerts H, Schmitt HJ. A serological study of organisms possibly associated with pertussis-like coughing. *Pediatr Infect Dis J* 1998; **17**: 645–649.
- Aoyama T, Ide Y, Watanabe J, Takeuchi Y, Imaizumi A. Respiratory failure caused by dual infection with *Bordetella pertussis* and respiratory syncytial virus. *Acta Paediatr Japon* 1996; **38**: 282–285.
- Moshal KL, Hodinka RL, McGowan KL. Concomitant viral and *Bordetella pertussis* infections in infants. *Pediatr Infect Dis J* 1998; **17**: 353–354.
- Dagan R, Hall CB, Menegus MA. Atypical bacterial infections explained by a concomitant virus infection. *Pediatrics* 1985; **76**: 411–414.
- Tristram DA, Miller RW, McMillan JA, Weiner LB. Simultaneous infection with respiratory syncytial virus and other respiratory pathogens. *Am J Dis Child* 1988; **142**: 834–836.
- Thomson F, Masters IB, Chang AB. Persistent cough in children and the overuse of medications. *J Paediatr Child Health* 2002; **38**: 578–581.
- Brémont F, Micheau P, Le Roux P, Brouard J, Pin I, Fayon M. Étiologie de la toux chronique de l'enfant: analyse de 100 dossiers. *Arch Pediatr* 2001; **8**(suppl 3): 645–649.
- Hallander HO, Gnärpe J, Gnärpe H, Olin P. *Bordetella pertussis*, *Bordetella parapertussis*, *Mycoplasma pneumoniae*, *Chlamydia pneumoniae* and persistent cough in children. *Scand J Infect Dis* 1999; **31**: 281–286.
- Gottfarb P, Brauner A. Children with persistent cough—outcome with treatment and role of *Moraxella catarrhalis*? *Scand J Infect Dis* 1994; **26**: 545–551.
- Gilberg S, Njamkepo E, Parent du Chatelet I *et al.* Evidence of *Bordetella pertussis* infection in adults presenting with persistent cough in a French area with very high whole-cell vaccine coverage. *J Infect Dis* 2002; **186**: 415–418.
- Strebel P, Nordin J, Edwards K *et al.* Population-based incidence of pertussis among adolescents and adults, Minnesota, 1995–1996. *J Infect Dis* 2001; **183**: 1353–1359.
- Nagel J, de Graaf S, Schijf-Evers D. Improved serodiagnosis of whooping cough caused by *Bordetella pertussis* by determination of IgG anti-LPF antibody levels. *Dev Biol Stand* 1985; **61**: 325–330.
- de Melker HE, Versteegh FGA, Conyn-Van Spaendonck MA *et al.* Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with *Bordetella pertussis*. *J Clin Microbiol* 2000; **38**: 800–806.
- Herrmann KL. Antibody detection. In: Lennette EH, Halonen P, Murphy FA, eds. *Laboratory diagnosis of infectious diseases. Principles and practice*, Vol. II. Berlin: Springer Verlag, 1988; 76–101.
- van der Zee A, Agterberg C, Peeters M, Mooi F, Schellekens J. A clinical validation of *Bordetella pertussis* and *Bordetella parapertussis* polymerase chain reaction: comparison with culture and serology using samples from patients with suspected whooping cough from a highly immunized population. *J Infect Dis* 1996; **174**: 89–96.
- van der Zee A, Agterberg C, Peeters M, Schellekens J, Mooi FR. Polymerase chain reaction assay for pertussis:

- simultaneous detection and discrimination of *Bordetella pertussis* and *Bordetella parapertussis*. *J Clin Microbiol* 1993; **31**: 2134–2140.
18. Dorigo-Zetsma JW, Zaat SAJ, Wertheim-van Dillen PME *et al.* Comparison of PCR, culture, and serological tests for diagnosis of *Mycoplasma pneumoniae* respiratory tract infection in children. *J Clin Microbiol* 1999; **37**: 14–17.
 19. Meijer A, van der Vliet JA, Schouls LM, de Vries A, Roholl PJ, Ossewaarde JM. Detection of microorganisms in vessel wall specimens of the abdominal aorta: development of a PCR assay in the absence of a gold standard. *Res Microbiol* 1998; **149**: 577–583.
 20. Andeweg AC, Bestebroer TM, Huybregts M, Kimman TG, de Jong JC. Improved detection of rhinoviruses in clinical samples by using a newly developed nested reverse transcription-PCR assay. *J Clin Microbiol* 1999; **37**: 524–530.
 21. Fouchier RAM, Bestebroer TM, Herfst S, van der Kemp L, Rimmelzwaan GF, Osterhaus ADME. Detection of influenza A viruses from different species by PCR amplification of conserved sequences in the matrix gene. *J Clin Microbiol* 2000; **38**: 4096–4101.
 22. Claas EC, Sprenger MJ, Kleter GE, van Beek R, Quint WG, Masurel N. Type-specific identification of influenza viruses A, B and C by the polymerase chain reaction. *J Virol Methods* 1992; **39**: 1–13.
 23. van den Hoogen BG, de Jong JC, Groen J *et al.* A newly discovered human pneumovirus isolated from young children with respiratory tract disease. *Nat Med* 2001; **7**: 719–724.
 24. Cubie HA, Inglis JM, Leslie EE, Edmunds AT, Totapally B. Detection of respiratory syncytial virus in acute bronchiolitis in infants. *J Med Virol* 1992; **38**: 283–287.
 25. Myint S, Johnston S, Sanderson G, Simpson H. Evaluation of nested polymerase chain methods for the detection of human coronaviruses 229E and OC43. *Mol Cell Probes* 1994; **8**: 357–364.
 26. Bartlett JG, Ryan KJ, Smith TF, Wilson WR. *Laboratory diagnosis of lower respiratory tract infections. Cumitech 7A*. Washington, DC: American Society for Microbiology, 1987; 13–14.
 27. Nicholson KG, Kent J, Hammersley V, Cancio E. Acute viral infections of upper respiratory tract in elderly people living in the community: comparative, prospective, population based study of disease burden. *BMJ* 1997; **315**: 1060–1064.
 28. Jartti T, Lehtinen P, Vuorinen T *et al.* Respiratory picornaviruses and respiratory syncytial virus as causative agents of acute expiratory wheezing in children. *Emerg Infect Dis* 2004; **10**: 1095–1101.
 29. van Bente I, Koopman L, Niesters B *et al.* Predominance of rhinovirus in the nose of symptomatic and asymptomatic infants. *Pediatr Allergy Immunol* 2003; **14**: 363–370.
 30. Heijnen MLA, Dorigo-Zetsma JW, Bartelds AIM, Wilbrink B, Sprenger MJW. Surveillance of respiratory pathogens and influenza-like illnesses in general practices—The Netherlands, winter 1007/98. *Euro Surveill* 1999; **4**: 81–84.
 31. Gunnarsson RK, Holm SE, Söderström M. The prevalence of potentially pathogenic bacteria in nasopharyngeal samples from individuals with a long-standing cough—clinical value of a nasopharyngeal sample. *Fam Pract* 2000; **17**: 150–155.
 32. Azevedo AMN, Durigon EL, Okasima V *et al.* Detection of influenza, parainfluenza, adenovirus and respiratory syncytial virus during asthma attacks in children older than 2 years old. *Allergol Immunopathol (Madr)* 2003; **31**: 311–317.
 33. Nelson KE, Gavitt F, Batt MD, Kallick CA, Reddi KT, Levin S. The role of adenoviruses in the pertussis syndrome. *J Pediatr* 1975; **86**: 335–341.
 34. Sturdy PM, Court SDM, Gardner PS. Viruses and whooping-cough. *Lancet* 1971; **2**: 978–979.
 35. Connor JD. Evidence for an etiologic role of adenoviral infection in pertussis syndrome. *N Engl J Med* 1970; **283**: 390–394.
 36. van Gageldonk-Lafeber AB, Bartelds A, Heijnen MLH *et al.* A case-control study on acute respiratory infections of patients in general practices in the Netherlands, October 2000–September 2003. *Clin Microbiol Infect* 2004; **10**(suppl 3): 91–92.
 37. Johnston SL, Pattemore PK, Sanderson G *et al.* Community study of role of viral infections in exacerbations of asthma in 9–11 year old children. *BMJ* 1995; **310**: 1225–1229.
 38. Thumerelle C, Deschildre A, Bouquillon C *et al.* Role of viruses and atypical bacteria in exacerbations of asthma in hospitalized children: a prospective study in the Nord-Pas de Calais region (France). *Pediatr Pulmonol* 2003; **35**: 75–82.
 39. Wesley AG, Windsor IM. Viral infections in clinical pertussis. *S Afr Med J* 1983; **64**: 577–578.
 40. Banerji A, Bell A, Mills EL *et al.* Lower respiratory tract infections in Inuit infants on Baffin Island. *Can Med Assoc J* 2001; **164**: 1847–1850.
 41. Keller MA, Aftandelians R, Connor JD. Etiology of pertussis syndrome. *Pediatrics* 1980; **66**: 50–55.
 42. Cimolai N, Wensley D, Sear M, Thomas ET. *Mycoplasma pneumoniae* as a cofactor in severe respiratory infections. *Clin Infect Dis* 1995; **21**: 1182–1185.
 43. Drews AL, Atmar RL, Glezen WP, Baxter BD, Piedra PA, Greenberg SB. Dual respiratory virus infections. *Clin Infect Dis* 1997; **25**: 1421–1429.
 44. Juvén T, Mertsola J, Waris M *et al.* Etiology of community-acquired pneumonia in 254 hospitalized children. *Pediatr Infect Dis J* 2000; **19**: 293–298.
 45. Hakonarson H, Maskeri N, Carter C, Hodinka RL, Campbell D, Grunstein MM. Mechanism of rhinovirus-induced changes in airway smooth muscle responsiveness. *J Clin Invest* 1998; **102**: 1732–1741.
 46. Tsolia MN, Psarras S, Bossios A *et al.* Etiology of community-acquired pneumonia in hospitalized school-age children: evidence for high prevalence of viral infections. *Clin Infect Dis* 2004; **39**: 681–686.
 47. van der Hoek L, Pyrc K, Jebbink MF *et al.* Identification of a new human corona virus. *Nat Med* 2004; **10**: 368–373.
 48. Mejías A, Chávez-Bueno S, Ramilo O. Human metapneumovirus: a not so new virus. *Pediatr Infect Dis J* 2004; **23**: 1–7.
 49. Bogaert D, Engelen MN, Timmers-Reker AJM *et al.* Pneumococcal carriage in children in The Netherlands: a molecular epidemiological study. *J Clin Microbiol* 2001; **39**: 3316–3320.